CNR Institutional Research Information System

AZZOLINA, ANTONINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.498
NA - Nord America 790
EU - Europa 374
SA - Sud America 286
AF - Africa 30
OC - Oceania 2
Totale 2.980
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 744
SG - Singapore 622
CN - Cina 351
BR - Brasile 226
HK - Hong Kong 211
VN - Vietnam 139
NL - Olanda 97
IT - Italia 87
FR - Francia 83
KR - Corea 50
IN - India 35
GB - Regno Unito 32
JP - Giappone 31
AR - Argentina 28
CA - Canada 21
DE - Germania 17
MX - Messico 15
EC - Ecuador 12
ID - Indonesia 11
ZA - Sudafrica 10
ES - Italia 9
FI - Finlandia 9
IL - Israele 7
BD - Bangladesh 6
IQ - Iraq 6
KE - Kenya 6
RU - Federazione Russa 6
AE - Emirati Arabi Uniti 4
CO - Colombia 4
EG - Egitto 4
JM - Giamaica 4
LT - Lituania 4
SA - Arabia Saudita 4
SE - Svezia 4
UY - Uruguay 4
AZ - Azerbaigian 3
IE - Irlanda 3
MA - Marocco 3
PE - Perù 3
PL - Polonia 3
PY - Paraguay 3
TR - Turchia 3
UZ - Uzbekistan 3
VE - Venezuela 3
BO - Bolivia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GR - Grecia 2
KZ - Kazakistan 2
NP - Nepal 2
PH - Filippine 2
PK - Pakistan 2
PT - Portogallo 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
UA - Ucraina 2
AT - Austria 1
AU - Australia 1
BG - Bulgaria 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CL - Cile 1
CZ - Repubblica Ceca 1
EE - Estonia 1
GT - Guatemala 1
HR - Croazia 1
KG - Kirghizistan 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MG - Madagascar 1
MK - Macedonia 1
NO - Norvegia 1
NR - Nauru 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
TG - Togo 1
Totale 2.980
Salva come PNG Salva come JPEG
Città #
Santa Clara 362
Singapore 360
Hong Kong 211
Hefei 117
San Jose 84
Beijing 76
Lauterbourg 65
Ho Chi Minh City 53
Seoul 49
Ashburn 36
Hanoi 25
Tokyo 25
Los Angeles 21
São Paulo 20
New York 18
Dallas 16
Mumbai 14
Buffalo 9
Montreal 9
Palermo 9
Orem 8
Frankfurt am Main 7
Haiphong 7
Portsmouth 7
Rio de Janeiro 7
Bengaluru 6
Brasília 6
Council Bluffs 6
Helsinki 6
London 6
Mexico City 6
Minamishinagawa 6
Nairobi 6
Phoenix 6
Potenza 6
Toronto 6
Biên Hòa 5
Brooklyn 5
Da Nang 5
Denver 5
Düsseldorf 5
Johannesburg 5
Quito 5
Thái Bình 5
Amsterdam 4
Belo Horizonte 4
Chennai 4
Houston 4
Milan 4
Montevideo 4
Salvador 4
Ankara 3
Atlanta 3
Baku 3
City of London 3
Dhaka 3
Dublin 3
Elk Grove Village 3
Forest City 3
Goiânia 3
Guayaquil 3
Kingston 3
Lappeenranta 3
Lima 3
Manaus 3
Montes Claros 3
New Delhi 3
Newark 3
Ninh Bình 3
Poplar 3
Porto Alegre 3
Ribeirão Preto 3
San Francisco 3
Santo André 3
Santos 3
Stockholm 3
Tashkent 3
Anápolis 2
Aparecida de Goiânia 2
Aracaju 2
Aversa 2
Belém 2
Betim 2
Bogotá 2
Bologna 2
Bratislava 2
Buenos Aires 2
Bình An 2
Bắc Ninh 2
Cagliari 2
Cairo 2
Camaçari 2
Campinas 2
Caruaru 2
Chicago 2
Clorinda 2
Cotia 2
Curitiba 2
Davao City 2
Delhi 2
Totale 1.873
Salva come PNG Salva come JPEG
Nome #
Potential uses of olive oil secoiridoids for the prevention and treatment of cancer: A narrative review of preclinical studies 95
Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation 84
Identification of an LPS-Induced Chemo-Attractive Peptide from Ciona robusta 83
Cationic Solid-lipid nanoparticles as DNA carriers. 79
Antitumor effects of the selective cyclooxygenase-1 inhibitor SC-560 is potentiated by inhibiton of MEK/ERK pathway in human hepatocellular carcinoma cells 76
The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma 64
New Insights into the Behavior of NHC-Gold Complexes in Cancer Cells 63
COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer Cells. 61
RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma 61
The novel NF-kB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. 58
In vitro and in vivo antitumor activity of the proteasome inhibitor MLN2238 in hepatocellular carcinoma cells 56
Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells 53
Hepatocellular Carcinoma: A Difficult Cancer to Treat 52
GSK-3 in liver diseases: Friend or foe? 52
Aromatase and amphiregulin are correspondingly expressed in human liver cancer cells. 51
The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment 50
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway 47
Biocompatible Lipid Nanoparticles as Carriers to Improve Curcumin Efficacy in Ovarian Cancer Treatment 47
Development of nimesulide loaded solid lipid nanoparticles. 46
Emerging Use of Nanotechnology for the Treatment of Liver Diseases 45
Cationic Solid Lipid Nanoparticles as Non Viral Vectors for the Inhibition of Hepatocellular Carcinoma Growth by RNA Interference 45
Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma 44
COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. 42
Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells 42
Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma 40
The response to simulated hypogravity is dependent on the proliferation state and temperature in FRTL-5 thyroid cells 39
Substance P selectively activates TNF-a mRNA in rat uterine immune cells: a neuroimmune link 39
Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. 38
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. 38
Structure-based identification of a non-covalent thioredoxin reductase inhibitor with proven ADMET suitability 37
Antitumor effects of DHMEQ, a novel NF-kB inhibitor, in human liver cancer cells is mediated through a reactive oxygen species-dependent mechanism. 36
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. 36
Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response. 35
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 34
Cationic solid-lipid nanoparticles for gene delivery. 34
Evidence that brain mast cells can modulate neuroinflammatory responses by tumour necrosis factor-a production 33
Molecular mechanisms of sorafenib action in liver cancer cells. 33
Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response. 32
From targets to targeted therapies in Hepatocellular carcinoma 32
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells. 32
Microgravity and cellular homeostasis: effects of simulated hypogravity on FRTL-5 thyroid cells. 32
Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery 31
Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation 31
Potentiation of antitumor effects of NSAIDs by inhibition of MEK/ERK activity in human hepatocellular carcinoma cells. 31
The selective COX-1 inhibitor SC-560 inhibits cell growth and induces apoptosis in human hepatocellular carcinoma cells 31
Altered gene expression profiles in liver cancer cells upon sorafenib treatment. 29
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 29
Combination of DHMEQ and Celecoxib synergistically exert anti-tumoral effects in human hepatoma cells. 29
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells 28
The selective COX-1 inhibitor SC-560 inhibits cell growth and induces apoptosis in human hepatocellular carcinoma cells. 28
Gene expression profiling of human liver cancer cells following celecoxib treatment. 28
The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells 28
Antitumor effects of the selective cyclooxygenase-1 inhibitor SC-560 is potentiated by inhibiton of MEK/ERK pathway in human hepatocellular carcinoma cells. 28
Influence of MEK/ERK signaling on apoptosis induced by selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatocellular carcinoma cells. 27
G. Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 27
Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies 27
The novel NF-kB inhibitor DHMEQ suppresses the growth of human hepatic cancer cells through redox-dependent signaling. 27
DHMEQ, a novel NF-kb inhibitor, anticancer activity through induction of reactive oxygen species-dependent mechanism in human hepatoma cells. 27
Solid-lipid nanoparticles for gene delivery to cells. 27
Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle. 26
Inhibition of MEK/ERK pathway enhances apoptosis induced by selective COX-1 and COX-2 inhibitors in human hepatocellular carcinoma cells. 26
The multikinase inhibitor Sorafenib exhibits a strong cytotoxic effect in liver cancer cells through a MEK/ERK signaling-independent mechanism 26
DHMEQ and Celecoxib synergistically exert anti-tumoral activities in human liver cancer cells. 25
Inhibition of MEK/ERK pathway enhances apoptosis induced by selective COX-1 and COX-2 inhibitors in human hepatocellular carcinoma cells. 25
Altered gene expression profiles in liver cancer cells upon sorafenib treatment. 25
Histamine and spontaneously released mast cell granules affect the cell growth of human hepatocellular carcinoma cells 24
INVOLVEMENT OF p38 AND JNK mapks PATHWAYS IN SUBSTANCE P-INDUCED PRODUCTION OF TNF - BY PERITONEAL MAST CELLS 24
Potentiation of antitumor effects of NSAIDs by inhibition of MEK/ERK activity in human hepatocellular carcinoma cells 23
Growth suppression and apoptosis induction in human hepatoma cells by DHMEQ, a novel NF-KB inhibitor, is mediated through a ROS-dependent mechanism. 23
Influence of MEK/ERK signaling on apoptosis induced by selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatocellular carcinoma cells 23
Microgravity and cellular homeostasis:effects of stimulated hypogravity on FRTL-5 thyroid cells. 23
The selective COX-1 inhibitor SC-560 suppresses cell growth and induces apoptosis in human hepatocellular carcinoma cells 22
Substance P induces TNF-alpha and IL-6 production through NFkB in peritoneal mast cells 22
The selective COX-1 inhibitor SC-560 suppresses cell growth and induces apoptosis in human hepatocellular carcinoma cells. 21
Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies. 21
Solid lipid nanoparticles (SLNs) containing nimesulide: preparation, characterization and in cytotoxicity studies 20
The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells 20
Synthesis and characterization of polyaminoacidic polycations for gene delivery. 20
DHMEQ, a novel NF-kb inhibitor, anticancer activity through induction of reactive oxygen species-dependent mechanism in human hepatoma cells. 20
Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism 16
Involvement of p38 and JNK MAPKs pathways in substance P-induced production of TNF-α by peritoneal mast cells 16
Substance P induces TNF-α and IL-6 production through NFκB in peritoneal mast cells 14
Totale 3.014
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.180
article - articoli 5.390
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 281
Totale 14.851
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20248 0 0 0 0 0 0 0 0 0 0 4 4
2024/20251.227 8 5 81 48 301 68 8 82 29 116 275 206
2025/20261.779 126 192 182 307 309 58 218 138 125 84 40 0
Totale 3.014